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Chapter 3
Hepatic expression of constitutively 
active IKKβ in mice induces low-grade 
inflammation, but does not cause 
insulin resistance: a protective role 
for A20?
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Obesity is associated with low-grade chronic inflammation in adipose tissue. Adipose 
tissue inflammation has been implicated in the development of insulin resistance. 
Whether hepatic inflammation also contributes to insulin resistance is still unclear. 
In this study, we aimed to investigate the effect of hepatic inflammation, induced 
by activation of nuclear factor (NF)-κB, on the development of insulin resistance. To 
investigate this, we used mice that express a constitutively active form of the inhibitor 
of κB-kinase-β in hepatocytes (IKKβcahep). Insulin resistance was evaluated by a glucose 
and insulin tolerance test in 4-month-old mice on a chow diet and mice fed a high fat, 
high cholesterol (HFC) diet for 12 weeks. Liver samples were taken for histology, gene 
expression and western blot analysis. IKKβcahep mice showed a marked increase of the 
NF-κB subunit P65 in the nucleus and an increase in macrophage infiltration in the liver 
compared to wild type (WT) mice. However, only a mild increase of inflammatory NF-κB 
target genes was observed on both diets. Despite the mild hepatic inflammation, 
IKKβcahep mice did not show glucose intolerance or insulin resistance in comparison to 
WT controls on either diet. To explain this mild inflammatory phenotype, we measured 
the expression of the NF-κB inhibitors A20, IκBα and Commd1 and observed a 20-fold 
increase in A20 expression in livers of IKKβcahep mice on a chow diet and a HFC diet 
compared to WT mice. This increase in A20 expression was not mirrored by a parallel 
increase in IκBα and Commd1 expression, as these genes were only 2-fold upregulated 
in IKKβcahep mice. These results indicate that low-grade hepatic inflammation observed 
in IKKβcahep mice does not induce insulin resistance. Upregulation of the NF-κB inhibitor 
A20 may dampen liver inflammation and may serve as a protective mechanism against 
severe inflammation and the development of insulin resistance in IKKβcahep mice. Future 
studies are directed at investigating whether downregulation of A20 can increase hepatic 
inflammation and can thereby induce insulin resistance in IKKβcahep mice.




The occurrence of the metabolic syndrome in obesity is a tremendous burden in western 
society, as it comes with many health risks and gigantic healthcare costs. Features of the 
metabolic syndrome include visceral obesity, dyslipidemia, insulin resistance, hypertension, 
hepatic lipid accumulation and metabolic inflammation [1]. Insulin resistance is thought 
to be a major driver of the metabolic syndrome [1] and also precedes the development 
of type 2 diabetes [2]. The exact mechanisms that cause insulin resistance are still under 
investigation. However, numerous evidence points towards a causal role of metabolic 
inflammation in expanding adipose tissue [3]. Indeed, in obesity, an increased number 
of macrophages and elevated cytokine expression is found in adipose tissue, and this is 
associated with a decrease in insulin sensitivity [4-7]. Consistent with this, knockdown 
of inflammatory genes has been shown to protect against the development of insulin 
resistance in many mouse models [8-10]. Moreover, silencing of inflammatory genes in 
adipose tissue macrophages was recently shown to protect mice against the development 
of insulin resistance [11]. 
Metabolic inflammation in obesity is, however, not restricted to the adipose tissue; 
the liver is also a strong contributor to the development of this inflammation [12]. Indeed, 
hepatic inflammation has been implicated in the development of insulin resistance, but 
results have been controversial. On the one hand, expression of human constitutively 
active inhibitor of κB-kinase-β (IKKβ) in the liver of mice activates nuclear factor (NF)-κB 
and thereby induces hepatic inflammation, causing hepatic as well as systemic insulin 
resistance in mice [13], while knockdown of IKKβ in mice produces opposite results [14]. 
On the other hand, we recently showed that activation of NF-κB by a gain-of-function 
mutation in the Tnfα receptor does not induce insulin resistance, despite an increased 
level of hepatic inflammation in these mice [15]. Moreover, in another study in which NF-
κB was inhibited by administration of the IκBα super-repressor, mice were protected from 
insulin resistance, without alterations in the most important pro-inflammatory cytokines 
[16]. This suggests that the protection against insulin resistance is independent from 
suppression of NF-κB-driven hepatic inflammatory gene expression. Therefore, we sought 
to evaluate the role of NF-κB-driven hepatic inflammation in the development of insulin 
resistance to further elucidate if insulin resistance is directly linked to hepatic inflammation. 
To investigate this, we assessed the development of insulin resistance in mice expressing 
the constitutively active form of murine IKKβ [17] in hepatocytes (IKKβcahep) subjected to 





B6(Cg)-Gt(ROSA)26Sortm4(Ikbkb)Rsky/J were obtained from the Jackson Laboratory (Bar Harbor, 
ME). These mice have a construct with a mutated form of murine IKKβ that is preceded 
by a STOP cassette [17]. This mutated form of IKKβ is constitutively active (IKKβca) 
because two serine amino acids (S177E, S181E) have been substituted by glutamate in 
the activation loop of the kinase domain. The STOP cassette is flanked by LoxP sites which 
can be recognized by Cre recombinase. To achieve liver-specific expression of IKKβca, we 
crossed the mice with C57BL/6 mice expressing Cre recombinase under control of the 
hepatocyte-specific albumin promotor (AlbCre) (Jackson Laboratory). AlbCre expression 
than leads to removal of the STOP cassette located upstream of IKKβca and as a result 
IKKβca is expressed in hepatocytes. Male mice heterozygous for AlbCre and homozygous 
for IKKβca (IKKβcahep mice) and control mice homozygous for IKKβca that do not have 
the AlbCre transgen (WT mice) were used for all experiments, unless otherwise stated. 
They were kept on a 12-hour light/12-hour dark cycle, with ad libitum access to food and 
water. Mice received either a regular chow diet or a high fat, high cholesterol (HFC) diet 
containing 21% fat from milk butter and 0.2% cholesterol (Scientific Animal Food and 
Engineering, Villemoisson-sur-Orge, France). Mice on a chow diet were sacrificed at 4 
months (young mice) and 12 months of age (middle-aged mice), and mice fed a HFC diet 
were kept on the diet for 12 weeks and were sacrificed at 7-8 months of age. All mice 
were sacrificed after a 6-hour fasting period by a heart puncture while they were under 
isoflurane-induced anesthesia. A subset of mice was injected with 0.75 U/kg insulin 15 
min before sacrifice to measure insulin signaling. All animal experiments were approved 
by the ethics committee of the University of Groningen. 
Oral glucose tolerance test and insulin tolerance test
To investigate insulin resistance, an oral glucose tolerance test (OGTT) and an insulin 
tolerance test (ITT) were performed. Before both tests, mice were fasted for 6 hours 
and basal glucose levels were measured. During the OGTT, mice were given a bolus of 
glucose (2 g/kg) and glucose clearance was determined by measuring blood glucose 
levels at 15, 30, 60, 90 and 120 minutes after glucose administration. In addition, blood 
samples were taken before and 15, 30, 60 and 120 min after glucose administration for 
the determination of insulin levels. Samples were spun at 3000g for 10 min at 4˚C and 
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insulin levels were measured in plasma using a commercially available ELISA kit (Alpco 
Diagnostics, Salem, NH). Fasted glucose and insulin levels were used to calculate the 
homeostasis model assessment of insulin resistance (HOMA-IR) ((fasted glucose (mmol/l) 
x fasted insulin (mU/l))/ 22,5). For the ITT, mice were injected with 0.5 U/kg. Blood glucose 
concentrations were measured at 15, 30, 60, 90 and 120 min after injection. 
Real-time PCR
Frozen liver samples were homogenized in Qiazol reagent (Qiagen, Venlo, the Netherlands) 
and RNA was isolated according to the manufacturer’s instructions. Before cDNA 
synthesis, genomic DNA was eliminated by incubating RNA with genomic DNA wipe-out 
buffer (Quantitect Reverse Transcription, Qiagen). cDNA was synthesized according to 
the protocol of a commercially available kit (Quantitect Reverse Transcription, Qiagen). 
Real-time (RT)-PCR was performed using SYBR green supermix (Bio-Rad, Veenendaal, 
the Netherlands) and expression of genes was normalized to Ppia. Genes were expressed 
as fold induction compared to WT mice. PCR-disposables were purchased from Greiner 
Bio-One (Alphen aan den Rijn, The Netherlands). All primer sequences are listed in Table 1.
TaBle 1. Primer sequences.













To determine hepatic lipid accumulation, lipids were extracted from crushed liver samples 
using the protocol described by Bligh and Dyer [18]. Hepatic triglyceride and cholesterol 




For immunoblot analysis of whole liver tissue, frozen liver samples were homogenized in 
a lysis buffer containing protease and phosphatase inhibitors. For immonoblot analysis 
of nuclear and cytosolic fractions, fresh liver samples were homogenized in a hypotonic 
buffer. Nuclear and cytosolic fractions were separated according to the protocol of a 
commercially available kit (Active Motif, La Hulpe, Belgium). The purity of the fractions 
was confirmed by immunoblot analysis of proteins specific for the nucleus and cytosol 
(data not shown). Protein concentrations were determined with the Bradford protein 
assay (Bio-Rad). Equal amounts of proteins were separated using SDS-PAGE. Proteins 
were transferred to a polyvinylidene difluoride membrane (GE Healthcare Life Sciences, 
Diegem, Belgium) and membranes were incubated O/N with an antibody against 
the protein of interest at 4˚C (FLAG, Sigma-Aldrich, Zwijndrecht, The Netherlands; 
P65, α-Tubulin, Lamin A/C and pAKT Ser473, Cell Signaling Technology, Leiden, the 
Netherlands). The following day, membranes were incubated with a secondary antibody 
with horse-radish peroxidase (Goat-anti-rabbit: Bio-Rad or Goat-anti-mouse: Sigma-
Aldrich) and proteins were visualized using enhanced chemiluminescence reaction 
reagent. Pictures were taken with Gel Doc XR+ Imaging system (Bio-Rad) and protein 
bands were quantified using Image Lab 3.0.1 (Bio-Rad).
Histological analysis
Liver samples were fixed in 4% paraformaldehyde or frozen for histological analysis. 
Paraformaldehyde fixed liver samples were embedded in paraffin and 4 μm thick liver 
sections were cut for a hemotoxyllin-eosin (HE) staining. Frozen liver samples were sectioned 
at 5 μm and stained with an antibody against CD68 (FA11, Abcam, Cambridge, UK) or 
CD11b (Abcam). CD68 and CD11b stained sections were scanned using NanoZoomer 2.0-
HT slide scanner (Hamamatsu, Herrsching am Ammersee, Germany) and quantified using 
Aperio ImageScope (Leica Biosystems Imaging Inc., CA, USA). 
Hepatocyte and Kupffer cell isolation
WT and IKKβcahep mice were anesthetized and cannulated in the portal vein for the 
hepatocyte and Kupffer cell isolation procedure. Mice were first infused with carbogenated 
Hanks I buffer for 10 minutes and then with carbogenated Hanks II buffer with collagenase 
(84 U/ml) for approximately 30 minutes. When the liver structure started to disintegrate, 
the liver was excised and the capsule of Glisson was removed. The cells were suspended 
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in ice cold Krebs buffer containing 0.01 g/ml BSA and were washed and centrifuged. 
The supernatant was decanted and used for the isolation of Kupffer cells. The pellet, 
containing hepatocytes, was resuspended in Qiazol (Qiagen) for the isolation of RNA. The 
Kupffer cell suspension was centrifuged at 400 g for 10 min at 4˚C and the pellet was 
suspended in PBS. To isolate Kupffer cells, a Nycodenz gradient of 14.5% (bottom layer) 
and 8.2% (top layer) was prepared from a 60% Nycodenz solution (Serva, Heidelberg, 
Germany). The cell suspension was carefully pipetted on this gradient and spun at room 
temperature for 18 min at 1600 g. The lower interphase layer, containing Kupffer cells, 
was transferred to a new tube containing PBS and spun for 5 min at 3000 g at 4˚C. To 
isolate RNA, the pellet was resuspended in Qiazol (Qiagen). The purity of Kupffer cell and 
hepatocyte samples was confirmed by measuring the gene expression of hepatocyte and 
Kupffer cell specific genes (Apoa1 and Cd68 respectively) (data not shown). 
Statistical analysis
Mann-Whitney U tests were used to determine differences between the genotypes and 
the threshold for significance was set at p < 0.05. Statistical analyses were performed 
using GraphPad Prism 5.0 (San Diego, USA) and data are presented as mean ± SEM. 
Results
Body weight and hepatic lipid accumulation are not affected by 
hepatocyte-specific expression of IKKβca 
To study the role of hepatic inflammation in the etiology of insulin resistance, we 
generated mice expressing the constitutively active form of inhibitor of κB-kinase-β (IKKβ) 
specifically in hepatocytes (IKKβcahep) by crossing B6(Cg)-Gt(ROSA)26Sortm4(Ikbkb)Rsky/J 
mice (Jackson Laboratory) with Albumin-Cre recombinase (AlbCre) transgenic mice 
(Jackson Laboratory). Mice homozygous for IKKβca, but not expressing AlbCre were used 
as wild type (WT) mice. The expression of the IKKβca in hepatocytes was determined by 
immunoblot analysis of the FLAG protein attached to the IKKβca construct. The FLAG 
protein could not be detected in WT samples, but became visible in mice heterozygous 
for IKKβca (Fig. 1A). Marked expression of FLAG was detected in mice homozygous for 




Figure 1. Characteristics of IKKβcahep mice fed a chow diet. (A) The expression of the 
constitutively active form of IKKβ (IKKβca) in hepatocytes was determined by immunoblot 
analysis of the FLAG protein attached to the IKKβca construct in wild type (WT) mice and 
mice heterozygous and homozygous for IKKβca (IKKβcahep het and IKKβcahep ho, respectively). 
Body weight (B), liver weight (C), hepatic cholesterol (D) and hepatic triglycerides were 
determined in WT and homozygous IKKβcahep mice at 4 months of age. (F) Representative 
pictures of hemotoxyllin-eosin (HE) stained liver sections were taken for histological analysis. 
N = 5-6 for all experiments. 
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Body weight (Fig. 1B) and liver weight (Fig. 1C) were not affected by hepatic expression 
of IKKβca. In addition, no differences in hepatic cholesterol (Fig. 1D) or triglyceride 
(Fig. 1E) levels were observed between transgenic and WT animals. This was confirmed 
by histological analysis of HE-stained liver sections (Fig. 1F). 
Mild hepatic inflammation in IKKβcahep mice fed a chow diet 
To investigate if IKKβca induces the activation of NF-κB, we assessed the nuclear 
translocation of the NF-κB subunit P65 using both nuclear and cytosolic extracts from 
livers of WT and IKKβcahep mice fed a chow diet. IKKβca expression elevated both 
cytosolic and nuclear levels of P65, suggesting increased NF-κB activation (Fig. 2A). In 
addition, gene expression of various NF-κB target genes was determined by quantitative 
RT-PCR. Despite the increased P65 protein levels in the nucleus, of the pro-inflammatory 
genes measured, only Il-6 expression was significantly increased in IKKβcahep mice 
(Fig. 2B). In addition, we found a 1.5-fold increase in the anti-apoptotic NF-κB target 
genes Ciap-1 and Traf-1 (Fig. 2B). The NF-κB inhibitors Commd1, IκBα and A20 are also 
NF-κB target genes and were all upregulated in IKKβcahep mice (Fig. 2B). Remarkably, 
A20 levels were 24-fold higher in IKKβcahep mice than in WT mice (Fig. 2B). 
To further investigate whether increased NF-κB activation induces liver inflammation, 
we stained liver sections for CD68 and CD11b (Fig. 2C). CD68 is a marker for Kupffer 
cells and macrophages and it was 3-fold higher in IKKβcahep mice as compared to WT 
mice (Fig. 2D). CD11b, a marker for activated and infiltrated macrophages, was also 
significantly elevated in IKKβcahep mice as compared to WT mice (Fig. 2E). Overall, these 
data suggest that hepatocyte-specific IKKβca expression results in increased NF-κB 
activation and mild hepatic inflammation. 
Hepatic IKKβca expression does not affect glucose tolerance or insulin 
resistance on a chow diet
We next assessed whether this mild inflammatory phenotype in IKKβcahep mice is associated 
with reduced insulin sensitivity in mice fed a chow diet. Although a trend towards an 
increase in plasma glucose (Fig. 3A) and insulin (Fig. 3B) levels was observed in IKKβcahep 
mice, this did not reach statistical significance. Based on these values, the calculation 
of the homeostasis model assessment of insulin resistance (HOMA-IR) revealed a 2-fold 
increase in insulin resistance (Fig. 3C). However, this was not confirmed by the glucose 
tolerance test (Fig. 3D) or the insulin tolerance test (Fig. 3E) as no differences were found 
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between the genotypes during these tests. This may be explained by the fact that these 
tests measure systemic, but not hepatic, insulin resistance. To investigate hepatic insulin 
resistance, we injected a subset of mice with insulin before sacrifice and measured the 
phosphorylation of AKT in the liver. However, no differences were observed between 
the two genotypes (Fig. 3F). These results indicate that the low-grade inflammation in 
IKKβcahep mice does not accelerate the development of insulin resistance. 
Figure 2. Hepatic expression of IKKβca induces mild hepatic inflammation in mice fed a 
chow diet. (A) Immunoblot analysis of the NF-κB subunit P65 in nuclear and cytosolic fractions of 
4-month old wild type (WT) mice and mice expressing the constitutively active form of IKKβ 
(IKKβcahep). (B) The expression of NF-κB target genes involved in inflammation, apoptosis and NF-
κB inhibition was measured by real-time PCR in liver homogenates. (C) Frozen liver sections were 
stained with the macrophage markers CD68 and CD11b. The amount of cells positive for CD68 
(D) and CD11b (E) was quantified using Aperio ImageScope. N = 6 for all experiments. 
* P < 0.05 versus WT mice. 




Figure 3. Mild hepatic inflammation does not induce insulin resistance in IKKβcahep mice 
fed a chow diet. Glucose (A) and insulin (B) levels were measured and used to calculate the 
homeostasis model assessment of insulin resistance (HOMA-IR) (C) in 4-month old wild type (WT) 
and mice expressing the constitutively active form of IKKβ (IKKβcahep) (N = 5-6). An oral glucose 
tolerance test (D) and an insulin tolerance test (E) were performed to measure insulin resistance (N 
= 10-12). (F) The phosphorylation of AKT was measured and quantified by immunoblot analysis in 
mice injected with insulin 15 minutes before sacrifice (N = 6). * P < 0.05 versus WT mice.
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Feeding mice a HFC diet does not aggravate inflammation or insulin 
resistance in IKKβcahep mice
Since the inflammatory phenotype in mice fed a chow diet appears to be relatively mild, 
we next investigated if a metabolic challenge, by feeding the mice a high fat, high 
cholesterol (HFC) diet for 12 weeks, may trigger the development of insulin resistance 
in IKKβcahep mice. Analysis of inflammatory gene expression revealed a significant 
increase in Il-1β and Il-6 expression in IKKβcahep mice (Fig. 4A), which was comparable 
to that observed in IKKβcahep on a chow diet (Fig. 2B). Similar to mice on a chow diet, 
hepatocyte-specific IKKβca expression did not affect body weight (Fig. 4B). However, 
liver weight was reduced in IKKβcahep mice fed a HFC diet as compared to WT mice on 
the same diet (Fig. 4C). This was not explained by differences in hepatic steatosis, as 
hepatic cholesterol and triglyceride accumulation did not differ between both groups of 
mice (Figs. 4D-E). Nevertheless, no differences were found in the HOMA-IR (WT, 5.48 ± 
1.23; IKKβcahep, 6,98 ± 0.80, ns), and in insulin tolerance between WT and IKKβcahep fed 
a HFC-diet (Fig. 4F). Moreover, glucose tolerance and insulin secretion during the OGTT 
were also similar in both groups (Figs. 4G-H), suggesting that a metabolic challenge does 
not aggravate the development of insulin resistance in IKKβcahep mice. 
Expression of IKKβca in the liver induces hepatocyte-specific A20 expression
To investigate whether the 24-fold induction in the NF-κB inhibitor, A20, may explain 
the mild inflammatory phenotype of IKKβcahep mice by dampening the levels of hepatic 
inflammation in these mice, we measured the expression of A20 in female, aged and HFC-
fed male mice. As expected, A20 expression was increased in IKKβcahep mice regardless of 
the gender and age of the mice, or type of diet used (Fig. 5A). Consistent with enhanced 
A20 expression, protein expression was significantly increased in IKKβcahep mice fed a 
chow diet (Fig. 5B). To investigate which cell-type was responsible for the increased A20 
expression in IKKβcahep mice, we separated hepatocytes from Kupffer cells and measured 
A20 expression in both fractions. Upregulation of A20 expression was observed in the 
hepatocyte fraction (Fig. 5C) and not in the Kupffer cell fraction (Fig. 5D), suggesting 
that A20 may indeed be responsible for the mild inflammatory phenotype in IKKβcahep 
mice. 
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Figure 4. Feeding IKKβcahep mice a high fat, high cholesterol diet does not aggravate 
inflammation or insulin resistance. (A) The expression of inflammatory genes was measured 
in liver homogenates by real-time PCR in wild type (WT) and mice expressing the constitutively 
active form of IKKβ (IKKβcahep) that were fed a high fat, high cholesterol diet for 12 weeks 
(N = 6-8). Body weight (B) and liver weight, expressed as percentage of body weight (C), were 
determined at sacrifice (N = 16). Hepatic lipids were extracted and hepatic cholesterol (C) and 
hepatic triglycerides (D) were measured (N = 6-7). Insulin resistance was assessed by performing 
an insulin tolerance test (F), an oral glucose tolerance test (G) and by measuring insulin levels 
during the oral glucose tolerance test (H) (N = 7-8). * P < 0.05 versus WT mice.
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Figure 5. The NF-κB inhibitor A20 is highly upregulated in the liver of IKKβcahep mice. (A) 
Hepatic A20 gene expression was measured in female mice kept on a chow diet (N = 6), 12-month 
old (aged) male mice kept on a chow-diet (N = 5) and male mice fed a high fat, high cholesterol 
(HFC) diet for 12 weeks (N = 6-8). (B) Protein A20 levels were determined by immunoblot analysis 
in 4-month old male mice kept on a chow diet (N = 6). Hepatocytes (C) and Kupffer cells (D) were 
separated by gradient centrifugation and the fractions were used to measure A20 gene expression 
(N = 2). * P < 0.05 versus WT mice. WT, wild type; IKKβca, constitutively active IKKβca. 




Although frequently associated with obesity, insulin resistance and T2D, a causal 
role for hepatic inflammation in the development of insulin resistance has become 
controversial [19]. To further elucidate whether insulin resistance is directly linked to 
hepatic inflammation, we evaluated the role of NF-κB-driven hepatic inflammation in 
the development of insulin resistance using mice with hepatocyte-specific expression of 
IKKβca. We show that IKKβcahep mice did not develop insulin resistance despite a mild 
inflammatory phenotype. In addition, HFC feeding did not aggravate the development 
of insulin resistance in IKKβcahep mice as compared to WT mice. This indicates that low-
grade hepatic inflammation does not induce insulin resistance.
Our results are in line with the dissociation between hepatic inflammation and insulin 
resistance recently found in mice with a gain-of-function mutation in the Tnfα receptor 
[15]. In this study, we found that chronic low-grade inflammation in the liver, which was 
10-100 fold lower than the inflammation achieved by a single TNFα injection, did not lead 
to insulin resistance [15]. Nevertheless, our results do contrast with the study from Cai et 
al. showing that hepatic expression of human IKKβca resulted in not only hepatic, but also 
systemic insulin resistance in mice [13]. These discrepancies may be explained by the type 
of constructs that were used in both studies. Cai et al. used a human form of IKKβca and 
the construct was designed to include the albumin-promotor [13]. In the current study, 
we used murine IKKβca, which was activated by removal of the STOP-cassette when mice 
were crossed with mice expressing AlbCre. Since murine and human IKKβca might not 
have the same effect on inflammation and insulin resistance in mice, this might explain this 
discrepancy. An alternative explanation could be that the degree of hepatic inflammation 
is lower in our study compared to the study from Cai et al. [13] and Sunami et al. [20]. 
Indeed, Cai et al. found that the expression of the inflammatory genes Il-1β and Il-6 is 4- 
and 9-fold higher in mice expressing IKKβca in the liver [13], whereas we only found a 2- 
and 3-fold increase in these genes (Figs. 2B and 4A). Moreover, Cai et al., found increased 
IL-6 levels in plasma and enhanced expression of Il-6 target genes in muscle, indicating 
that inflammation in their study is not contained to the liver, which may explain the effects 
on systemic insulin resistance. Thus, the inflammation achieved in our IKKβcahep mice may 
be too low to have an effect on insulin resistance. Whether the mild inflammation in 
our study also becomes systemic remains to be determined. Nevertheless, it is difficult to 
compare the severity of inflammation between the mouse models, as this requires a direct 
comparison between the different models. 
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Although the low levels of hepatic inflammation provide a possible explanation for the 
lack of an effect on insulin resistance and hepatic insulin signaling, this does not take 
into account the direct effect of IKKβ on insulin signaling. IKKβ has been reported to 
induce serine phosphorylation of insulin receptor substrate 1 (IRS1), which inhibits insulin 
signaling [21-24]. This was also shown to happen in the liver of mice expressing human 
IKKβca [13]. Therefore, the presence of IKKβca alone is expected to interfere with insulin 
signaling. However, there are also studies that show that IKKβ does not affect insulin 
signaling. Overexpression of IKKβ did not induce serine phosphorylation of IRS1 or inhibit 
glucose uptake in 3T3-L1 adipocytes [25]. In addition, pharmacological inhibition of IKKβ 
and knockdown of IKKβ did not improve insulin signaling in 3T3-L1 adipocytes and MEFs 
[25]. Moreover, in the absence of inflammatory stimuli, inhibition of IKKβ by aspirin 
did not affect insulin signaling in 3T3-L1 adipocytes [26]. Only when cells were treated 
with TNFα, aspirin improved insulin signaling [26]. These results suggest that only in 
the presence of inflammatory stimuli, IKKβ induces insulin resistance. Since the levels 
of inflammation in IKKβcahep mice were low, this may explain why expression of IKKβca 
does not lead to hepatic or systemic insulin resistance in our study. 
The mild hepatic inflammation observed in IKKβcahep mice is likely to be explained 
by the remarkably high increase in A20 expression in the liver (Figs. 2B and 5A-C). A20 is 
a potent suppressor of the transcription factor NF-κB [27], but it also a target gene of NF-
κB [28]. Hence, A20 expression is likely to be induced in response to IKKβca expression 
in hepatocytes. This is supported by the fact that A20 expression was only increased in 
hepatocytes and not in Kupffer cells (Figs. 5C-D). Nevertheless, it is surprising that of the 
measured NF-κB target genes only A20 is highly upregulated by IKKβca expression in the 
liver. It would be interesting to elucidate the underlying mechanism, as this may lead to 
new insights in the regulation of inflammation. The importance of A20 in the regulation 
of inflammation is supported by the fact that mice with A20 deficiency are not viable. 
A20 deficiency leads to inflammation in multiple organs [29] and A20 was also shown 
to play a crucial role in the liver. In a model of acute hepatitis and in a model of ischemia 
reperfusion induced liver injury, A20 expression protected mice from dying [30,31]. 
A20 inhibits NF-κB by ubiquitination and deubiquitination of targets upstream of NF-κB 
(reviewed by [32,33]). Furthermore, it binds to NEMO and inhibits the phosphorylation 
of IKKβ by Tak1, thereby reducing NF-κB translocation [34]. Interestingly, the inhibitory 
activity of A20 is increased by IKKβ, suggesting that NF-κB activation induced by IKKβca 
is partly self-limiting [35]. However, the inhibition by A20 is apparently not complete in 
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IKKβcahep mice, as we still see increased P65 levels in the nucleus (Fig. 2A). Collectively, 
these findings suggest that A20 may be produced in IKKβcahep mice as a compensatory 
mechanism to protect mice from hepatic inflammation. There could also be other 
compensatory mechanisms occurring in IKKβcahep mice. The slight increase in Commd1 
expression in IKKβcahep is definitely not one of these mechanisms, as crossing these mice 
with hepatocyte specific Commd1 knock-out mice did not affect hepatic inflammation 
(Paulina Bartuzi and Bart van de Sluis, personal communication). We cannot exclude 
any other compensatory mechanism at this point. To investigate if other genes are also 
affected, we are currently sequencing mRNA from IKKβcahep mice. 
If the lack of insulin resistance is indeed explained by the low levels of inflammation, 
the anti-inflammatory effects of A20 may protect the IKKβcahep mice indirectly from 
developing insulin resistance. Despite the well-described anti-inflammatory properties 
of A20, little is known about its role in insulin resistance and type 2 diabetes. To further 
elucidate the role of A20 in insulin resistance, we aim to cross IKKβcahep mice with mice 
lacking A20 in hepatocytes and investigate the effects on hepatic inflammation and 
insulin resistance.
In conclusion, these results indicate that low-grade hepatic inflammation observed 
in IKKβcahep mice does not induce insulin resistance. Upregulation of the NF-κB inhibitor 
A20 appears to dampen liver inflammation and might thereby protect against the 
development of insulin resistance in IKKβcahep mice. Studies investigating hepatic A20 
deficiency in IKKβcahep mice are currently in progress to further elucidate this. 
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